In solid tumors, the studies identified miR-125a as an anti-oncogene that inhibits tumorigenesis and cancer progression.20, 23 In breast cancer, miR-125a has been demonstrated to inhibit cancer growth and migration by suppressing ERBB2 and ERBB3.30 The antitumor functions also confirmed in gastric cancer through ERBB2/miR-125a loop31 and by regulating angiogenesis through VEGF-A.32 Moreover, Ninio-Many et al.33 indicated miR-125a modulates molecular pathway of motility and migration via Fyn expression in prostate cancer cells. The gene discussed is ERBB2; the disease is breast carcinoma.